Article
Immunology
Kerstin H. Mair, Maria Stadler, Mahsa Adib Razavi, Armin Saalmuller, Wilhelm Gerner
Summary: This study demonstrates the expression and function of NKp46 on porcine plasmacytoid dendritic cells (pDCs). It was found that the majority of porcine pDCs express NKp46 and have an active signaling pathway upon NKp46 triggering, leading to cytokine production. However, unlike NK cells, NKp46 on porcine pDCs does not seem to be involved in cytotoxicity.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Binhui Zhou, Toby Lawrence, Yinming Liang
Summary: Plasmacytoid dendritic cells (pDCs) are a special subtype of dendritic cells that produce massive amounts of type I interferon (IFN-I) and play a pivotal role in antiviral immunity. However, in many types of cancer, tumor-infiltrating pDCs do not respond to Toll-like receptor (TLR) stimulation, leading to reduced IFN-alpha production and promoting tumor growth.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Bo Deng, Yuli Lin, Yusheng Chen, Shuai Ma, Qian Cai, Wenji Wang, Bingji Li, Tingyan Liu, Peihui Zhou, Rui He, Feng Ding
Summary: The study revealed that pDCs play a detrimental role in AKI by producing IFN-alpha, inducing apoptosis of renal tubular epithelial cells, promoting immune cell infiltration and proinflammatory cytokine production, exacerbating kidney damage. The results indicate that IFN-alpha is a key factor mediating the functions of pDCs in AKI pathogenesis.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Meiling Zheng, Zhi Hu, Xiaole Mei, Lianlian Ouyang, Yang Song, Wenhui Zhou, Yi Kong, Ruifang Wu, Shijia Rao, Hai Long, Wei Shi, Hui Jing, Shuang Lu, Haijing Wu, Sujie Jia, Qianjin Lu, Ming Zhao
Summary: This study compares the differences between cutaneous lesions from DLE and SLE patients and healthy controls using single-cell RNA sequencing data. The findings reveal differential immune cell recruitment, cell type, and gene expression, highlighting potential therapeutic targets for lupus erythematosus.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Kenjiro Takao, Makiko Suzuki, Ryo Miyazaki, Minoru Miyake, Kazuya Akimitsu, Katsuaki Hoshino
Summary: D-Allose, a rare sugar, has been found to inhibit cytokine production by murine dendritic cells stimulated with ssRNA or CpG DNA by attenuating the phosphorylation of MAPK family members.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Nadine Tarantino, Marion Leboyer, Arthur Bouleau, Nora Hamdani, Jean Romain Richard, Wahid Boukouaci, Wu Ching-Lien, Ophelia Godin, Djaouida Bengoufa, Philippe Le Corvoisier, Caroline Barau, Katia Ledudal, Patrice Debre, Ryad Tamouza, Vincent Vieillard
Summary: Accumulated evidence points to immune dysfunction as a significant factor in psychotic disorders. This study found major dysfunction of NK cells in first-episode psychosis patients, with impairment correlated to the progression of psychotic symptoms in subsequent schizophrenia and bipolar disorder diagnoses.
MOLECULAR PSYCHIATRY
(2021)
Review
Immunology
Kosuke Minaga, Tomohiro Watanabe, Akane Hara, Tomoe Yoshikawa, Ken Kamata, Masatoshi Kudo
Summary: Activation of plasmacytoid dendritic cells (pDCs) can lead to autoimmune diseases like SLE, psoriasis, AIP, and IgG4-RD. Research has shown that IFN-I and IL-33 produced by pDCs play a key role in the development of AIP and IgG4-RD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Hiroyuki Kitamura, Tetsuya Tanigawa, Takuya Kuzumoto, Yuji Nadatani, Koji Otani, Shusei Fukunaga, Shuhei Hosomi, Fumio Tanaka, Noriko Kamata, Yasuaki Nagami, Koichi Taira, Satoshi Uematsu, Toshio Watanabe, Yasuhiro Fujiwara
Summary: The study demonstrates that IFN-alpha and plasmacytoid dendritic cells (pDCs) play a proinflammatory role in the pathophysiology of radiation-induced esophagitis.
Article
Oncology
Vladimir Koucky, Kamila Hladikova, Eliska Taborska, Jan Boucek, Marek Grega, Radek Spisek, Anna Fialova
Summary: This study revealed that the functional capacity of tumor-infiltrating plasmacytoid dendritic cells (pDCs) in HPV-negative head and neck squamous cell carcinoma patients is significantly affected by immunosuppressive cytokines such as IL-10 and TNF alpha, leading to dysfunctional pDCs in the tumor microenvironment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Dermatology
Tara Bardawil, Samar Khalil, Mazen Kurban, Ossama Abbas
Summary: Plasmacytoid dendritic cells infiltrate the skin in various infections, inflammations, and tumors, and can be identified in tissue using specific markers. Evaluating specific plasmacytoid dendritic cell-related parameters is a useful tool for differentiating skin diseases with overlapping features.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
(2021)
Article
Immunology
Nadine Szumilas, Odilia B. J. Corneth, Christian H. K. Lehmann, Heike Schmitt, Svenia Cunz, Jolie G. Cullen, Talyn Chu, Anita Marosan, Attila Mocsai, Vladimir Benes, Dietmar Zehn, Diana Dudziak, Rudi W. Hendriks, Lars Nitschke
Summary: Siglec-H regulates TLR-9-dependent inflammatory responses after virus infections, but not TLR-7 dependent responses. Lack of Siglec-H in pDCs leads to impaired Hck expression and downregulation of chemokine receptor CCR9, affecting pDC function.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Rebeca Arroyo Hornero, Juliana Idoyaga
Summary: Since their discovery, the identity and classification of plasmacytoid dendritic cells (pDCs) have been a subject of debate in the field. pDCs are distinct from other dendritic cell family members and may have dual origin from myeloid and lymphoid progenitors. They have the unique ability to quickly secrete abundant levels of type I interferon in response to viral infections and can activate T cells independently. This article provides an overview of the historic and current understanding of pDCs and argues for their inclusion within the dendritic cell network due to their role in linking innate and adaptive immune responses.
MOLECULAR IMMUNOLOGY
(2023)
Article
Immunology
Weihua Cao, Si Xie, Lu Zhang, Xiaoyue Bi, Yanjie Lin, Liu Yang, Yao Lu, Ruyu Liu, Min Chang, Shuling Wu, Ge Shen, Jianping Dong, Yao Xie, Minghui Li
Summary: In HBeAg-positive patients, those with lower baseline HBV DNA load and higher CD86(+) pDC% are more likely to achieve functional cure.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Wei Zhang, Seong-Min Lim, Juyoung Hwang, Srinivasan Ramalingam, Myunghee Kim, Jun-O Jin
Summary: MPLA enhances anti-cancer immunity mediated by anti-PD-L1 antibodies by activating pDCs and increasing IFN-α production.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Paoline Laurent, Chao Yang, Andre F. Rendeiro, Benjamin E. Nilsson-Payant, Lucia Carrau, Vasuretha Chandar, Yaron Bram, Benjamin R. tenOever, Olivier Elemento, Lionel B. Ivashkiv, Robert E. Schwartz, Franck J. Barrat
Summary: Lung-infiltrating macrophages play a role in the inflammation and lethality of COVID-19, despite not being infected by the virus. Plasmacytoid dendritic cells (pDCs) in the lungs produce interferons (IFN-I) in response to SARS-CoV-2, leading to macrophage activation. This interaction between pDCs and macrophages may contribute to the severity of the disease.
SCIENCE IMMUNOLOGY
(2022)
Article
Rheumatology
Sindhu R. Johnson, Dafna D. Gladman, Hermine Brunner, David Isenberg, Ann E. Clarke, Megan R. W. Barber, Laurent Arnaud, Paul R. Fortin, Marta Mosca, Alexandre E. Voskuyl, Susan Manzi, Cynthia Aranow, Anca Askanase, Graciela S. Alarcon, Sang-Cheol Bae, Nathalie Costedoat-Chalumeau, Jessica A. English, Guillermo J. Pons-Estel, Bernardo A. Pons-Estel, Rebecca Gilman, Ellen M. Ginzler, John G. Hanly, Soren Jacobsen, Kenneth Kalunian, Diane L. Kamen, Chynace Lambalgen, Alexandra Legge, S. Sam Lim, Anselm Mak, Eric F. Morand, Christine A. Peschken, Michelle Petri, Anisur Rahman, Rosalind Ramsey-Goldman, John A. Reynolds, Juanita Romero-Diaz, Guillermo Ruiz-Irastorza, Jorge Sanchez-Guerrero, Elisabet Svenungsson, Zahi Touma, Murray Urowitz, Evelyne Vinet, Ronald F. van Vollenhoven, Heather Waldhauser, Daniel J. Wallace, Asad Zoma, Ian N. Bruce
Summary: The SLICC, ACR, and Lupus Foundation of America are developing a revised SLE damage index (SDI) due to shifts in the concept of damage in SLE. A qualitative study was conducted to evaluate contemporary constructs in SLE damage and develop a conceptual framework for the revised SDI.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Robert W. Ike, Kenneth C. Kalunian
Summary: This article reviews the diverging interests of rheumatologists and orthopedists in arthroscopy and emphasizes the chances for reconciliation and cooperation. While the research potential of arthroscopy has mainly been realized by European rheumatologists, the use of new miniscopes suitable for office use could restore some of the lagging interest in arthroscopy for investigation.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
(2022)
Review
Rheumatology
Robert W. Ike, Kenneth C. Kalunian
Summary: Washing out knee joint contents can remove inflammatory material and be useful for management of various types of arthritis.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Rheumatology
Philip M. Carlucci, Jessica Li, Andrea Fava, Kristina K. Deonaraine, David Wofsy, Judith A. James, Chaim Putterman, Betty Diamond, Anne Davidson, Derek M. Fine, Jose Monroy-Trujillo, Mohamed G. Atta, Wade DeJager, Joel M. Guthridge, Kristin Haag, Deepak A. Rao, Michael B. Brenner, James A. Lederer, William Apruzzese, H. Michael Belmont, Peter M. Izmirly, Devyn Zaminski, Ming Wu, Sean Connery, Fernanda Payan-Schober, Richard Furie, Maria Dall'Era, Kerry Cho, Diane Kamen, Kenneth Kalunian, Jennifer Anolik, Jennifer Barnas, Mariko Ishimori, Michael H. Weisman, Jill P. Buyon, Michelle Petri
Summary: This study found that despite an inactive sediment or normal serologies, three-quarters of patients with UPCR <1 revealed histology showing class III, IV, V or mixed with accompanying activity and chronicity. These data support renal biopsy at thresholds lower than a UPCR of 1.
Meeting Abstract
Rheumatology
K. C. Kalunian, Y. Tanaka, I. Hupka, L. J. Zhang, M. Shroff, S. Werther, G. Abreu, C. Lindholm, R. Tummala
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Ronald F. van Vollenhoven, Kenneth C. Kalunian, Thomas Doerner, Bevra H. Hahn, Yoshiya Tanaka, Robert M. Gordon, Cathye Shu, Kaiyin Fei, Sheng Gao, Loqmane Seridi, Patrick Gallagher, Kim Hung Lo, Pamela Berry, Qing C. Zuraw
Summary: This study evaluated the efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus (SLE). The results showed that ustekinumab did not demonstrate superiority over placebo in terms of efficacy, and there were no significant differences in adverse events between the treatment groups.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Meeting Abstract
Rheumatology
R. van Vollenhoven, R. Furie, V. Werth, K. Kalunian, X. Huang, C. Musselli, C. Barbey, N. Franchimont
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Ann E. Clarke, John G. Hanly, Murray B. Urowitz, Yvan St. Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Vernon Farewell
Summary: The objective of this study was to estimate the costs associated with neuropsychiatric events in SLE. The study found that new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs. Indirect costs exceeded direct costs by 3.0 to 5.2 fold.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Kenneth C. Kalunian, Richard Furie, Eric F. Morand, Ian N. Bruce, Susan Manzi, Yoshiya Tanaka, Kevin Winthrop, Ihor Hupka, Lijin Jinny Zhang, Shanti Werther, Gabriel Abreu, Micki Hultquist, Raj Tummala, Catharina Lindholm, Hussein Al-Mossawi
Summary: This study investigates the long-term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE). The results show that anifrolumab is well-tolerated and has a favorable benefit-risk profile in patients with moderate-to-severe SLE receiving standard therapy.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader
Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, General & Internal
Michelle Petri, Ian N. Bruce, Thomas Doerner, Yoshiya Tanaka, Eric F. Morand, Kenneth C. Kalunian, Mario H. Cardiel, Maria E. Silk, Christina L. Dickson, Gabriella Meszaros, Lu Zhang, Bochao Jia, Youna Zhao, Conor J. McVeigh, Marta Mosca
Summary: Baricitinib, an oral inhibitor of Janus kinase 1 and 2, was evaluated as a treatment for patients with systemic lupus erythematosus (SLE) in a 52-week phase 3 study. The study found that baricitinib did not significantly improve SLE disease activity compared with placebo, and there were no new safety concerns.
Article
Rheumatology
Joy Buie, Lauren Bloch, Eric F. Morand, Ronald F. van Vollenhoven, Victoria P. Werth, Zahi Touma, Peter Lipsky, Kenneth Kalunian, Anca D. Askanase, L. Ines, Christopher Reed, MaryBeth Son, Timothy Franson, Karen Costenbader, Laura Eve Schanberg
Summary: Drug development in lupus has improved but lags behind other rheumatic diseases. Challenges in assessing lupus therapies include disease heterogeneity, study design limitations, and lack of validated biomarkers impacting regulatory decision-making. The meeting report addresses the need for standardized outcome measures to accelerate lupus therapeutics development and highlights ongoing efforts in outcome measure development.
LUPUS SCIENCE & MEDICINE
(2023)
Article
Rheumatology
Rashmi Dhital, Monica Guma, Dilli R. Poudel, Christina Chambers, Kenneth Kalunian
Summary: Care of young adults with SLE is challenging due to major life transitions co-occurring with chronic healthcare needs. This study found that young adults with SLE had higher rates of serious infection-related hospitalization compared to adults with SLE and young adults without SLE. Race/ethnicity and comorbidities were associated with hospitalization in young adults with SLE.
LUPUS SCIENCE & MEDICINE
(2023)
Article
Rheumatology
Yann Nguyen, Benoit Blanchet, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Joensen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Veronique Le Guern, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Nathalie Costedoat-Chalumeau
Summary: The study aimed to assess the association between severe nonadherence to hydroxychloroquine (HCQ), analyzed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates. Severe nonadherence was found to be independently associated with increased risk of SLE flares, early damage, and five-year mortality.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Health Care Sciences & Services
Maria Dall'Era, Kenneth Kalunian, Michael Eaddy, Augustina Ogbonnaya, Eileen Farrelly, Eric Turowski, Vanessa Birardi, Neil Solomons, Simrat Randhawa, Paola Mina-Osorio
Summary: This study aimed to evaluate treatment utilization and health care costs associated with active disease, low disease activity, and end-stage renal disease (ESRD) in patients with lupus nephritis (LN). The results showed that the treatment burden and costs were high for patients with active disease and ESRD, and treatments that allow patients to achieve and maintain low disease activity may help improve patient outcomes and reduce overall health care costs.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
(2023)